TY - JOUR
T1 - The impact of idiopathic pulmonary fibrosis on health state utility values
T2 - evidence from Australia
AU - Cox, Ingrid A.
AU - de Graaff, Barbara
AU - Ahmed, Hasnat
AU - Campbell, Julie
AU - Otahal, Petr
AU - Corte, Tamera J.
AU - Glaspole, Ian
AU - Moodley, Yuben
AU - Goh, Nicole
AU - Macansh, Sacha
AU - Walters, E. Haydn
AU - Palmer, Andrew J.
N1 - Funding Information:
This study is part of the QUality of LIfE and Costs AssociaTed with Idiopathic Pulmonary Fibrosis Study (QUIET-IPF) a project funded through the NHMRC Centre of Research Excellence in Pulmonary Fibrosis (GNT1116371), and by Foundation partner Boehringer Ingelheim and Program Partners Roche and Galapagos.
Funding Information:
TC reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, grants and personal fees from BMS, personal fees from Promedior, personal fees from Ad Alta, grants from Avalyn Pharma, grants from Biogen, outside the submitted work. IG reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, personal fees from Adalta, personal fees from Accendatech, personal fees from Avalyn Pharma, outside the submitted work; NG reports personal fees from Boehringer-Ingelheim, personal fees from Roche, personal fees from Astra Zeneca, non-financial support from Air Liquide, grants from Lung Foundation Australia, outside the submitted work. All other authors declare that they have no financial/competing interests.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2021/9
Y1 - 2021/9
N2 - Purpose: Idiopathic pulmonary fibrosis (IPF) is a progressive and universally fatal lung disease, characterised by increasing fibrosis of the lung parenchyma. In this study, we aimed to quantify the health state utility values (HSUVs) for Australians with IPF and to identify the factors affecting these HSUVs. Methods: Participants of the Australian IPF Registry (AIPFR), with data on EuroQoL five dimension—five level (EQ-5D-5L) profiles were included. Pulmonary function tests (PFTs) were used to assess disease severity using three IPF -based classification systems. Stepwise multivariable linear regression models assessed the relationship between HSUVs and important demographic and clinical parameters.Query Results: A total of 155 participants provided data for the analysis of HSUVs. For our base case, HSUVs ranged from − 0.57 to 1.00. Mean HSUVs for all participants was 0.65 (95% CI 0.61–0.70). In general, HSUVs decreased with increasing disease severity under all disease severity classification systems. Multivariable linear regression demonstrated a negative association between HSUVs, disease severity and having more than 2 comorbidities. Conclusions: Our study has shown that EQ-5D-5L has exhibited discriminatory sensitivity for the study population. We have demonstrated that disease severity and having more than two comorbidities was associated with lower HSUVs in Australians with IPF. Our findings support early diagnosis and appropriate evidence-based treatment to slow or prevent IPF progression; and identification and treatment of associated comorbidities to potentially improve health-related quality of life in people with IPF.
AB - Purpose: Idiopathic pulmonary fibrosis (IPF) is a progressive and universally fatal lung disease, characterised by increasing fibrosis of the lung parenchyma. In this study, we aimed to quantify the health state utility values (HSUVs) for Australians with IPF and to identify the factors affecting these HSUVs. Methods: Participants of the Australian IPF Registry (AIPFR), with data on EuroQoL five dimension—five level (EQ-5D-5L) profiles were included. Pulmonary function tests (PFTs) were used to assess disease severity using three IPF -based classification systems. Stepwise multivariable linear regression models assessed the relationship between HSUVs and important demographic and clinical parameters.Query Results: A total of 155 participants provided data for the analysis of HSUVs. For our base case, HSUVs ranged from − 0.57 to 1.00. Mean HSUVs for all participants was 0.65 (95% CI 0.61–0.70). In general, HSUVs decreased with increasing disease severity under all disease severity classification systems. Multivariable linear regression demonstrated a negative association between HSUVs, disease severity and having more than 2 comorbidities. Conclusions: Our study has shown that EQ-5D-5L has exhibited discriminatory sensitivity for the study population. We have demonstrated that disease severity and having more than two comorbidities was associated with lower HSUVs in Australians with IPF. Our findings support early diagnosis and appropriate evidence-based treatment to slow or prevent IPF progression; and identification and treatment of associated comorbidities to potentially improve health-related quality of life in people with IPF.
KW - EQ-5D-5L
KW - EuroQol five dimension
KW - Health related quality of life
KW - Health state utility values
KW - Idiopathic pulmonary fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85106296263&partnerID=8YFLogxK
U2 - 10.1007/s11136-021-02879-1
DO - 10.1007/s11136-021-02879-1
M3 - Article
C2 - 33999322
AN - SCOPUS:85106296263
VL - 30
SP - 2615
EP - 2632
JO - Quality of Life Research
JF - Quality of Life Research
SN - 0962-9343
IS - 9
ER -
